Innolake Biopharm has entered into a collaboration and license agreement with Ellipses Pharma Limited (“Ellipses”) to develop a clinical stage first-in-class antibody drug conjugate (ADC) ILB-3101, which is currently in a Phase I trial in China sponsored by Innolake. Under the partnership, Ellipses gains rights to develop a B7H3 targeted ADC with an Eribulin payload (ILB-3101) worldwide excluding greater China (ILB-3101 is designated as EP0028 by Ellipses). ILB-3101 has the potential to treat multiple tumor types and to address resistance to topoisomerase-1 based ADCs。Ellipses will initiate a Phase 1 clinical trial in the US with expansion to Europe and other territories following relevant regulatory approvals.

This partnership is a great validation of Innolake’s technology and capabilities. Having advanced ILB-3101 from early discovery through to the clinic, we are delighted to collaborate with Ellipses and look forward to bringing this innovative therapy to patients worldwide.